Table 4.
Antibodies to | Number (percent) patients positive | ||
---|---|---|---|
mAChR3-TFK-1 | M2 (IgG-type) | M2 (IgM-type) | |
Positive | Positive | Positive | 16 (42) |
Positive | Positive | Negative | 11 (29) |
Positive | Negative | Positive | 5 (13) |
Positive | Negative | Negative | 2 (5)* |
Negative | Positive | Positive | 2 (5) |
Negative | Positive | Negative | 2 (5) |
Parenthesis reflects % patients' sera showing none, stimulatory, or inhibitory anti-mAChR3 reactivity. All 36 anti-M2 positive sera reacted with the PDC-E2.
Of these two anti-M2 negative patients one had antibodies to nuclear dots (sp100) and one to gp210.